StockNews.com Begins Coverage on Evogene (NASDAQ:EVGN)

Analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research report issued on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners reaffirmed a “buy” rating on shares of Evogene in a research report on Friday, March 7th.

Evogene Price Performance

Shares of EVGN stock opened at $1.46 on Tuesday. The company has a market cap of $7.81 million, a P/E ratio of -0.33 and a beta of 1.28. The stock’s 50-day moving average is $1.52 and its 200 day moving average is $1.94. Evogene has a 1-year low of $1.20 and a 1-year high of $9.00.

Evogene (NASDAQ:EVGN) last released its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.78. The business had revenue of $1.61 million for the quarter, compared to analysts’ expectations of $3.63 million. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. During the same period last year, the business earned ($1.30) EPS.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Citadel Advisors LLC purchased a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned approximately 0.30% of Evogene at the end of the most recent quarter. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.